TriSalus Life Sciences
TLSI
44 hedge funds and large institutions have $125M invested in TriSalus Life Sciences in 2021 Q1 according to their latest regulatory filings, with 44 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
51.77% more ownership
Funds ownership: 0% → 51.77% (+52%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$27.9M |
| 2 |
PWAM
Park West Asset Management
San Francisco,
California
|
+$12.7M |
| 3 |
AC
Aristeia Capital
Greenwich,
Connecticut
|
+$11.7M |
| 4 |
LA
Linden Advisors
New York
|
+$7.41M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$7.26M |
Top Sellers
TLSI Hedge Fund Activity: Q1 2021 in Review
44 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in TriSalus Life Sciences (TLSI) for Q1 2021, worth a combined $125M.
Buyers outnumbered sellers: 44 funds opened new TLSI positions and 0 closed out — a net gain of 44 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was BlackRock, opening a new position worth an estimated $27.9M.
- 44 institutional investors held TriSalus Life Sciences (TLSI) as of Q1 2021, up from 0 in Q4 2020.
- Funds reported $125M of TriSalus Life Sciences stock for Q1 2021.
- 44 funds opened new TriSalus Life Sciences positions in Q1 2021 and 0 closed out, a net change of +44 holders.
- The largest TriSalus Life Sciences buyer in Q1 2021 was BlackRock, an estimated $27.9M added.
Based on aggregated 13F filings for Q1 2021.